Cancer classification using the Immunoscore: a worldwide task force.
Cancer classification using the Immunoscore: a worldwide task force.
复制标题
DOI：
10.1186/1479-5876-10-205
复制
发表时间：
2012-10-03
影响因子：
7.4
通讯作者：
Fox BA
中科院分区：
文献类型：
--
作者：
Galon J;Pagès F;Marincola FM;Angell HK;Thurin M;Lugli A;Zlobec I;Berger A;Bifulco C;Botti G;Tatangelo F;Britten CM;Kreiter S;Chouchane L;Delrio P;Arndt H;Asslaber M;Maio M;Masucci GV;Mihm M;Vidal-Vanaclocha F;Allison JP;Gnjatic S;Hakansson L;Huber C;Singh-Jasuja H;Ottensmeier C;Zwierzina H;Laghi L;Grizzi F;Ohashi PS;Shaw PA;Clarke BA;Wouters BG;Kawakami Y;Hazama S;Okuno K;Wang E;O'Donnell-Tormey J;Lagorce C;Pawelec G;Nishimura MI;Hawkins R;Lapointe R;Lundqvist A;Khleif SN;Ogino S;Gibbs P;Waring P;Sato N;Torigoe T;Itoh K;Patel PS;Shukla SN;Palmqvist R;Nagtegaal ID;Wang Y;D'Arrigo C;Kopetz S;Sinicrope FA;Trinchieri G;Gajewski TF;Ascierto PA;Fox BA
癌症临床结果的预测通常是通过对原发性肿瘤手术切除过程中获取的组织样本进行组织病理学评估来实现的。传统的肿瘤分期（美国癌症联合委员会/国际抗癌联盟 - TNM分类）总结了肿瘤负荷（T）、引流和区域淋巴结中癌细胞的存在情况（N）以及转移证据（M）等数据。然而，现在人们认识到，同一分期内的患者临床结果可能存在显著差异。当前的分类提供的预后信息有限，并且无法预测对治疗的反应。近期文献提到了宿主免疫系统在控制肿瘤进展方面的重要性。因此，有证据支持将免疫生物标志物纳入其中的观点，将其作为预测预后和治疗反应的工具。从大量人类癌症队列中收集的累积数据已经证明了免疫分类的影响，它具有预后价值，可能会增加美国癌症联合委员会/国际抗癌联盟TNM分类的重要性。因此，必须开始将“免疫评分”纳入传统分类中，从而提供一种重要的预后和潜在的预测工具。将这一参数作为生物标志物引入癌症分类，作为肿瘤常规诊断和预后评估的一部分，将有助于临床决策，包括对患者治疗进行合理分层。同样，定量免疫组织化学本身的复杂性，以及不同实验室之间的方案差异、对不同免疫细胞类型的分析、不一致的区域选择标准以及量化免疫浸润的不同方法，都凸显了实现检测方法标准化的迫切需求。为了在常规临床环境中推广免疫评分，一个国际工作组应运而生。这篇综述是对该倡议宣布以及2012年1月《转化医学杂志》社论的后续跟进。肿瘤的免疫表型分析可能会提供关键的新型预后信息。这次国际验证的结果可能会导致免疫评分作为癌症分类的一个新组成部分得以实施，即TNM - I（TNM - 免疫）。
Prediction of clinical outcome in cancer is usually achieved by histopathological evaluation of tissue samples obtained during surgical resection of the primary tumor. Traditional tumor staging (AJCC/UICC-TNM classification) summarizes data on tumor burden (T), presence of cancer cells in draining and regional lymph nodes (N) and evidence for metastases (M). However, it is now recognized that clinical outcome can significantly vary among patients within the same stage. The current classification provides limited prognostic information, and does not predict response to therapy. Recent literature has alluded to the importance of the host immune system in controlling tumor progression. Thus, evidence supports the notion to include immunological biomarkers, implemented as a tool for the prediction of prognosis and response to therapy. Accumulating data, collected from large cohorts of human cancers, has demonstrated the impact of immune-classification, which has a prognostic value that may add to the significance of the AJCC/UICC TNM-classification. It is therefore imperative to begin to incorporate the ‘Immunoscore’ into traditional classification, thus providing an essential prognostic and potentially predictive tool. Introduction of this parameter as a biomarker to classify cancers, as part of routine diagnostic and prognostic assessment of tumors, will facilitate clinical decision-making including rational stratification of patient treatment. Equally, the inherent complexity of quantitative immunohistochemistry, in conjunction with protocol variation across laboratories, analysis of different immune cell types, inconsistent region selection criteria, and variable ways to quantify immune infiltration, all underline the urgent requirement to reach assay harmonization. In an effort to promote the Immunoscore in routine clinical settings, an international task force was initiated. This review represents a follow-up of the announcement of this initiative, and of the J Transl Med. editorial from January 2012. Immunophenotyping of tumors may provide crucial novel prognostic information. The results of this international validation may result in the implementation of the Immunoscore as a new component for the classification of cancer, designated TNM-I (TNM-Immune).
登录
查看更多内容
影响因子：
11.2
作者：
Halama, Niels;Michel, Sara;Jaeger, Dirk
通讯作者：
Jaeger, Dirk
DOI：
10.1038/nrclinonc.2011.122
发表时间：
2011-08-09
期刊：
Nature reviews. Clinical oncology
影响因子：
--
作者：
通讯作者：
--
影响因子：
11.2
作者：
Erdag G;Schaefer JT;Smolkin ME;Deacon DH;Shea SM;Dengel LT;Patterson JW;Slingluff CL Jr
通讯作者：
Slingluff CL Jr
DOI：
10.1158/1078-0432.ccr-10-2234
发表时间：
2011-05-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Butterfield LH;Palucka AK;Britten CM;Dhodapkar MV;Håkansson L;Janetzki S;Kawakami Y;Kleen TO;Lee PP;Maccalli C;Maecker HT;Maino VC;Maio M;Malyguine A;Masucci G;Pawelec G;Potter DM;Rivoltini L;Salazar LG;Schendel DJ;Slingluff CL Jr;Song W;Stroncek DF;Tahara H;Thurin M;Trinchieri G;van Der Burg SH;Whiteside TL;Wigginton JM;Marincola F;Khleif S;Fox BA;Disis ML
通讯作者：
Disis ML
影响因子：
158.5
作者：
Pagès, F;Berger, A;Galon, J
通讯作者：
Galon, J